Download PDF
Klin Monbl Augenheilkd 2013; 230(9): 894-901
DOI: 10.1055/s-0033-1350764
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Kindliche Ablationes: ROP und Myopie

Childhood Retinal Detachment: ROP and Myopia
B. Müller
Augenklinik der Charité Universitätsmedizin Berlin (Standorte Virchow Klinikum und Klinikum Benjamin Franklin)
,
A. M. Joussen
Augenklinik der Charité Universitätsmedizin Berlin (Standorte Virchow Klinikum und Klinikum Benjamin Franklin)
› Author Affiliations
Further Information

Publication History

eingereicht 09 July 2013

akzeptiert 29 July 2013

Publication Date:
28 August 2013 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Dieser Übersichtsartikel diskutiert die pathophysiologischen Mechanismen und Behandlungsoptionen, die zu einer traktiven Ablatio bei der Frühgeborenenretinopathie und bei ROP-Residuen in der Jugend und im frühen Erwachsenenalter führen. Die retinale Vaskularisation ist inkomplett bei Frühgeborenen. Die Phase I der ROP besteht aus einem verzögerten Wachstum der Gefäße und einem Gefäßverlust nach der Geburt, die zu einer Hypoxie führt. Die anschließende Phase II resultiert in hypoxieinduzierten Gefäßproliferationen und – in der Konsequenz – in vitreoretinaler Traktion. Das anatomische und funktionelle Ergebnis bei der ROP ist abhängig von der vorherigen Therapie (z. B. Laserphotokoagulation in der peripher avaskulären Peripherie oder eine Anti-VEGF-Injektion). Während in der Literatur Wiederanlageraten von > 70 % bei der ROP Stadium IV a beschrieben wurden, sind die funktionellen und anatomischen Ergebnisse späterer Stadien limitiert. Residualformen der ROP können eher zu rhegmatogenen als traktiven Ablationes in der Kindheit bis zum frühen Erwachsenenalter führen. Die Myopie ist dabei mit der ROP assoziiert und kann die retinale Situation weiter beeinträchtigen und das Risiko für eine rhegmatogene Amotio erhöhen. Retinale Veränderungen in Assoziation mit einer ROP erfordern lebenslängliche Kontrollen.

Abstract

This article reviews the cause and treatment options for retinopathy of prematurity (ROP)-related tractional detachment and detachments in ROP residuals during childhood and early adulthood. Retinal vascularisation is incomplete after premature birth. Phase I of ROP consists of a delayed retinal vascular growth and vessel loss after premature birth resulting in hypoxia, phase II results in hypoxia-induced vascular proliferation and as a consequence to vitreoretinal traction. The anatomic and functional outcome of tractional detachment in ROP is determined by the previous treatment (e.g., laser to the avascular periphery or anti-VEGF). While the literature reports re-attachment rates > 70 % in ROP IV a, functional and anatomic outcome in the later stages is limited. ROP residuals may cause rhegmatogenous rather than tractional detachments in childhood or early adulthood. Myopia is associated with ROP and may further complicate the retinal situation and the risk for rhegmatogenous detachment. The retinal changes due to ROP warrant lifelong controls.

Schlüsselwörter

Netzhautchirurgie - Frühgeborenenretinopathie - Myopie - Ablatio im Kindesalter

Key words

vitreoretinal surgery - retinopathy of prematurity (ROP) - myopia - childhood retinal detachment
 

  • Literatur

  • 1 Cavallaro G, Filippi L, Bagnoli P et al. The pathophysiology of retinopathy of prematurity: an update of previous and recent knowledge. Acta Ophthalmol 2013; DOI: 10.1111/aos.12049.
    PubMedGoogle Scholar
  • 2 Gilbert CG, Fielder A, Gordillo L et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: implications for screening programs. Pediatrics 2005; 115: 518-525
    CrossrefPubMedGoogle Scholar
  • 3 Chiang MF, Arons RR, Flynn JT et al. Incidence of retinopathy of prematurity from 1996 to 2000: analysis of a comprehensive New York state patient database. Ophthalmology 2004; 111: 1317-1325
    CrossrefPubMedGoogle Scholar
  • 4 Ells A, Hicks M, Fielden M et al. Severe retinopathy of prematurity: longitudinal observation of disease and screening implications. Eye (Lond) 2005; 19: 138-144
    CrossrefPubMedGoogle Scholar
  • 5 Schwarz EC, Grauel EJ, Wauer RR. Kein Anstieg von Inzidenz, Therapie- und Erblindungsrate der Retinopathia praematurorum in einem universitären Perinatalzentrum Level 1 – eine prospektive Beobachtungsstudie von 1978–2007. Klin Monatsbl Augenheilkd 2011; 228: 208-219
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Holmström GE, Hellström A, Jakobsson PG et al. Swedish national register for retinopathy of prematurity (SWEDROP) and the evaluation of screening in Sweden. Arch Ophthalmol 2012; 130: 1418-1424
    Google Scholar
  • 7 Repka M, Tung B, Good W et al. Outcome of eyes developing retinal detachment during the early treatment for retinopathy of prematurity study. Arch Ophthalmol 2011; 129: 1175-1179
    CrossrefPubMedGoogle Scholar
  • 8 Good W. Early Treatment for Retinopathy of Prematurity Cooperative Group. Final results oft he Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 2004; 102: 233-250
    PubMedGoogle Scholar
  • 9 Mintz-Hittner H, Kennedy K, Chuang A. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011; 364: 603-615
    CrossrefPubMedGoogle Scholar
  • 10 Deutsche Ophthalmologische Gesellschaft; Berufsverband der Augenärzte Deutschlands, Gesellschaft für Neonatologie und Pädiatrische Intensivmedizin. Leitlinie zur augenärztlichen Screening-Untersuchung von Frühgeborenen. Ophthalmologe 2008; 105: 81-90
    CrossrefPubMedGoogle Scholar
  • 11 Fierson WM; American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists. Screening examination of premature infants for retinopathy of prematurity. Pediatrics 2013; 131: 189-195
    CrossrefPubMedGoogle Scholar
  • 12 Lee BJ, Kim JH, Heo H et al. Delayed onset atypical vitreoretinal traction band formation after an intravitreal injection of bevacizumab in stage 3 retinopathy of prematurity. Eye (Lond) 2012; 26: 903-909
    CrossrefPubMedGoogle Scholar
  • 13 Hu J, Blair MP, Shapiro MJ et al. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol 2012; 130: 1000-1006
    CrossrefPubMedGoogle Scholar
  • 14 Chen TC, Tsai TH, Shih YF et al. Long-term evaluation of refractive status and optical components in eyes of children born prematurely. Invest Ophthalmol Vis Sci 2010; 51: 6140-6148
    CrossrefPubMedGoogle Scholar
  • 15 Morrison DG, Emanuel M, Donahue SP. Risk of refractive pathology after spontaneously regressed ROP in emmetropic patients. J Pediatr Ophthalmol Strabismus 2010; 47: 141-144
    CrossrefPubMedGoogle Scholar
  • 16 Modrzejewska M, Grzesiak W, Karczewicz D et al. Refractive status and ocular axial length in preterm infants without retinopathy of prematurity with regard to birth weight and gestational age. J Perinat Med 2010; 38: 327-331
    PubMedGoogle Scholar
  • 17 Terry TL. Fibroblastic Overgrowth of Persistent Tunica Vasculosa Lentis in Infants Born Prematurely: II. Report of Cases–Clinical Aspects. Trans Am Ophthalmol Soc 1942; 40: 262-284
    PubMedGoogle Scholar
  • 18 Kinsey VE, Zacharias L. Retrolental fibroplasia; incidence in different localities in recent years and a correlation of the incidence with treatment given the infants. J Am Med Assoc 1949; 139: 572-578
    CrossrefPubMedGoogle Scholar
  • 19 Patz A, Hoeck LE, De La Cruz E. Studies on the effect of high oxygen administration in retrolental fibroplasia. I. Nursery observations. Am J Ophthalmol 1952; 35: 1248-1253
    PubMedGoogle Scholar
  • 20 Kinsey VE. Retrolental fibroplasia; cooperative study of retrolental fibroplasia and the use of oxygen. AMA Arch Ophthalmol 1956; 56: 481-543
    CrossrefPubMedGoogle Scholar
  • 21 Cross KW. Cost of preventing retrolental fibroplasia?. Lancet 1973; 2: 954-956
    PubMedGoogle Scholar
  • 22 Cats BP, Tan K. Retinopathy of prematurity: review of a four-year Period. Br J Ophthalmol 1985; 69: 500-503
    CrossrefPubMedGoogle Scholar
  • 23 Rankin SJ, Tubman TR, Halliday HL et al. Retinopathy of prematurity in surfactant treated infants. Br J Ophthalmol 1992; 76: 202-204
    CrossrefPubMedGoogle Scholar
  • 24 Rankin SJ, Tubman TR, Halliday HL et al. Surfactant and ROP incidence. Ophthalmology 1991; 98: 1148-1149
    PubMedGoogle Scholar
  • 25 The Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Arch Ophthalmol 1984; 102: 1130-1134
    CrossrefPubMedGoogle Scholar
  • 26 International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 2005; 123: 991-999
    CrossrefPubMedGoogle Scholar
  • 27 Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Arch Ophthalmol 1988; 106: 471-479
    CrossrefPubMedGoogle Scholar
  • 28 Zilis JD, deJuan E, Machemer R. Advanced retinopathy of prematurity. The anatomic and visual results of vitreous surgery. Ophthalmology 1990; 97: 821-826
    PubMedGoogle Scholar
  • 29 Seaber JH, Machemer R, Eliott D et al. Long-term visual results of children after initially successful vitrectomy for stage V retinopathy of prematurity. Ophthalmology 1995; 102: 199-204
    PubMedGoogle Scholar
  • 30 Alme AM, Mulhern ML, Hejkal TW et al. Outcome of retinopathy of prematurity patients following adoption of revised indications for treatment. BMC Ophthalmol 2008; 13: 8-23
    PubMedGoogle Scholar
  • 31 Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci 2000; 41: 1217-1228
    PubMedGoogle Scholar
  • 32 McLeod DS, Baba T, Bhutto IA et al. Co-expression of endothelial and neuronal nitric oxide synthases in the developing vasculatures of the human fetal eye. Graefes Arch Clin Exp Ophthalmol 2012; 250: 839-848
    CrossrefPubMedGoogle Scholar
  • 33 Grossniklaus HE, Kang SJ, Berglin L. Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res 2010; 29: 500-519
    CrossrefPubMedGoogle Scholar
  • 34 Stellungnahme von DOG, Retinologischer Gesellschaft und BVA zum Einsatz von Bevacizumab in der Therapie der Frühgeborenenretinopathie 20.12.2011. Im Internet: http://www.dog.org/wp-content/uploads/2009/08/ROP-Stellungnahme-20-12-2011.pdf Stand: 07.07.2013
    PubMedGoogle Scholar
  • 35 Lutty GA, McLeod D, Bhutto I et al. Effect of VEGF trap on normal retinal vascular development and oxygen-induced retinopathy in the dog. Invest Ophthalmol Vis Sci 2010; 51: 4039-4047
    PubMedGoogle Scholar
  • 36 Palmer EA, Hardy RJ, Dobson V et al. Cryotherapy for Retinopathy of Prematurity Cooperative Group. 15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity. Arch Ophthalmol 2005; 123: 311-318
    CrossrefPubMedGoogle Scholar
  • 37 Joshi MM, Ciaccia S, Trese MT et al. Posterior hyaloid contracture in pediatric vitreoretinopathies. Retina 2006; 26 (Suppl. 07) S38-S41
    CrossrefPubMedGoogle Scholar
  • 38 Hartnett ME, McColm JR. Fibrovascular organization in the vitreous following laser for ROP: implications for prognosis. Retina 2006; 26 (Suppl. 07) S24-S31
    CrossrefPubMedGoogle Scholar
  • 39 Quiram P, Lai M, Trese M. Surgical Management of Retinopathy of Prematurity. In: Joussen AM, et al., eds Retinal Vascular Disease. Heidelberg: Springer Publishers; 1997: 418-423
    Google Scholar
  • 40 Cusick M, Charles M, Agro E et al. Anatomical and visual results of vitreoretinal for stage 5 retinopathy of prematurity. Retina 2006; 26: 729-735
    CrossrefPubMedGoogle Scholar
  • 41 Lakhanpal RR, Sun RL, Albini T et al. Anatomical success rate after primary three- port lens-sparing vitrectomy in stage 5 retinopathy of prematurity. Retina 2006; 26: 724-728
    CrossrefPubMedGoogle Scholar
  • 42 Jandeck C, Kellner U, Heimann H et al. Vergleich der anatomischen und funktionellen Ergebnisse nach Laser und Kryotherapie für ROP. Ophthalmologe 2005; 102: 33-38
    Google Scholar
  • 43 Quinn GE, Dobson V, Davitt BV et al. Early Treatment for Retinopathy of Prematurity Cooperative Group. Progression of myopia and high myopia in the Early Treatment for Retinopathy of Prematurity study: findings at 4 to 6 years of age. J AAPOS 2013; 17: 124-128
    PubMedGoogle Scholar
  • 44 Harder BC, Schlichtenbrede FC, von Baltz S et al. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol 2013; 155: 1119-1124
    CrossrefPubMedGoogle Scholar
  • 45 Jandeck C, Kellner U, Foerster MH. Späte Komplikationen in Kindern mit vormals regredienter ROP. Klin Monatsbl Augenheilkd 2004; 221: 96-100
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Rosner M, Treister G, Belkin M. Epidemiology of retinal detachment in childhood and adolescence. J Pediatr Ophthalmol Strabismus 1987; 24: 42-44
    PubMedGoogle Scholar
  • 47 Wheeler DT, Dobson V, Chiang MF et al. Retinopathy of prematurity in infants weighing less than 500 grams at birth enrolled in the early treatment for retinopathy of prematurity study. Ophthalmology 2011; 118: 1145-1151
    CrossrefPubMedGoogle Scholar
  • 48 Huang J, Wen D, Wang Q. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes. N Engl J Med 2012; 367: 2052-2053
    CrossrefPubMedGoogle Scholar
  • 49 de Smet MD, Jonckx B, Vanhove M et al. Pharmacokinetics of ocriplasmin in vitreous. Invest Ophthalmol Vis Sci 2012; 53: 8208-8213
    CrossrefPubMedGoogle Scholar
  • 50 Wong SC, Capone jr. A. Microplasmin (ocriplasmin) in pediatric vitreoretinal surgery: update and review. Retina 2013; 33: 339-348
    CrossrefPubMedGoogle Scholar